Gordhandas S, et al. - Given the controversy around using hormone replacement therapy (HRT) in BRCA mutation carriers undergoing risk-reducing salpingo-oophorectomy (RRSO), researchers reviewed the available literature on the role of HRT in this high-risk population, with a focus on its impacts on quality of life, cardiovascular, bone, and brain health in these subjects. They also addressed the effect of HRT on breast cancer risk, with a discussion of HRT formulation and surgical approach. They found limited evidence on this topic, but data revealed several reported benefits of HRT after RRSO and it appeared to have no impact on breast cancer risk attenuation in BRCA mutation carriers. For BRCA mutation carriers, hormonal regimens with progestin may have a less advantageous breast cancer risk profile. These findings offer information to help with counseling this specific population.